A “skinny label” is one way that a generic drug can be commercialized in the US when only a subset of the brand’s uses lose exclusivity. The recent Supreme Court decision in the Caraco case may put a spotlight on the opportunities for “skinny label” generics. The article found here describes some of the issues and possible policy implications that may be associated with an increased use of “skinny labels.”
AI and market research sampling: battling bots and biases
Introduction and how the sampling industry works The landscape of market research sampling has had to evolve significantly in recent years. AI-driven bots are...